Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat shock protein SSA1 (SSA1) is a member of the highly conserved 70 kDa heat shock protein (Hsp70) family, primarily characterized in fungi such as Saccharomyces cerevisiae and the human pathogen Candida albicans [1, 5]. While traditionally recognized as an intracellular molecular chaperone that facilitates protein folding, translocation, and the degradation of misfolded proteins, SSA1 also localizes to the fungal cell wall and is secreted into the extracellular environment [3, 6]. In Candida albicans, SSA1 functions as a critical invasin by binding to host cell receptors, including E-cadherin and N-cadherin, which induces the endocytosis of the fungus into epithelial and endothelial cells [1, 6]. This mechanism is essential for the pathogen to breach host barriers and cause systemic or mucosal infections [2, 6]. As a therapeutic target, SSA1 is a focal point for the development of novel antifungal strategies due to its pivotal role in virulence and host-pathogen interactions [1, 4]. Experimental monoclonal antibodies, such as mAb 13F4, have demonstrated the ability to block SSA1-mediated invasion and improve survival in animal models of candidiasis [1, 2]. Additionally, SSA1 serves as a receptor for natural antimicrobial peptides like histatin 5 and can be modulated by thiol-reactive compounds that trigger the heat shock response [4, 7]. However, the high degree of conservation between fungal SSA1 and human Hsp70 homologs presents a significant challenge for drug specificity, as off-target effects could potentially disrupt host proteostasis [5, 14].
Inhibition of fungal adherence and endocytosis into host cells by blocking SSA1 binding to cadherins; modulation of the heat shock response via Hsf1 activation; direct neutralization of cell-surface invasin activity by monoclonal antibodies.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein SSA1 (SSA1).